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Medicinal mushrooms are widely used in East Asia for the treatment of various diseases,
especially in complementary cancer care. While there is a growing interest in medicinal
mushrooms in Western countries and an increasing number of pre-clinical studies indicate
distinct anti-cancer and regenerative properties, little is known about their potential relevance
for clinical practice. This review aims to provide an overview of the clinical evidence,
significance and potential role of medicinal mushrooms in complementary cancer care.
Scientific databases for (randomized) controlled clinical trials evaluating whole spectrum
formulations of medicinal mushrooms (mushroom powder and mushroom extracts) in
cancer patients during and/or after conventional oncological treatment were searched.
Eight studies met our inclusion criteria (eight randomized controlled trials, one controlled
clinical trial). The medicinal mushrooms investigated were Agaricus sylvaticus (two trials),
Agaricus blazei murill (two trials), Antrodia cinnamomea (one trial), Coriolus versicolor (one
trial) and Ganoderma lucidum (three trials); all were compared to placebo and administered
orally. A variety of cancer entities, outcomes and treatment durations were observed. Study
results suggested beneficial effects of medicinal mushrooms, particularly quality of life and
reduction of adverse effects of conventional therapies. Also, positive effects on antitumor
activity and immunomodulation were reported, e.g., an increased activity of natural killer
cells. In addition, results might suggest a longer survival of cancer patients receiving
mushroom preparations, although in most studies this was not significant when
compared to placebo. Adverse events of treatment with medicinal mushrooms were
poorly reported; gastrointestinal reactions and a decrease in platelet cell count occurred
in some cases. The methodological quality of most studies was generally unsatisfying and
most results were insufficiently reported in several respects.Medicinal mushroomsmay have
a therapeutic potential for cancer patients during and after conventional oncological care
with regards to quality of life, reduction of adverse effects of conventional care and possibly
other surrogate parameters like immune function. There is an urgent need to investigate the
safety and possible interactions of medicinal mushrooms. High-quality clinical research is
warranted in order to clarify the potential of medicinal mushrooms in cancer therapy.
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INTRODUCTION
Cancer is a major global threat and is the second leading cause of
death in industrialized countries after cardiovascular diseases
(Global Burden of Disease Cancer Collaboration et al., 2017).
Conventional cancer treatments include surgery, chemotherapy,
radiation, hormone-targeted therapies and immunotherapies.
These treatments can have various side effects such as
gastrointestinal symptoms, skin or mucous membrane
irritation, pain, fatigue, bone marrow suppression or
immunosuppression, which may lead to higher infection rates
and can significantly affect quality of life during or post
oncological treatments (Urruticoechea et al., 2010).
Despite the growing success of conventional personalized
cancer therapies, recurrence and metastases remain common,
depending on the type of cancer and the stage of disease (Miller
et al., 2019). In addition, a large number of patients are diagnosed
when in advanced stages, leaving little treatment options but for
palliative care (Haun et al., 2017).
The use of complementary and integrative medicine (CIM) is
widespread and widely accepted in cancer patients (Astin, 1998;
Ernst and Cassileth, 1998). Studies have shown that 20–50% of
cancer patients use some form of CIM therapies as an add-on to
conventional treatments (Ernst and Cassileth, 1998; Grant et al.,
2019). Medicinal mushrooms have been used in traditional Asian
medical systems continually for several centuries (Wasser, 2010).
Mushrooms have been identified to possess many medicinal
functions (Wasser, 2010; Wasser, 2014), including antioxidant
(Geng et al., 2016), antimicrobial, anti-inflammatory (Shigesue
et al., 2000), immunomodulating (Gao et al., 2013), antitumoral
(Fan et al., 2011; Reis et al., 2015), hepatoprotective (Zhang et al.,
2002), antidiabetic (Kim et al., 2010), prebiotic properties
(Singdevsachan et al., 2016). These properties were primarily
demonstrated in in vitro studies. Mushrooms are high in protein
(up to 40%), vitamins, fiber, minerals, trace elements and are low
in calories and cholesterol (Wasser, 2010). Higher basidiomycetes
mushrooms (pillar mushrooms/stand mushrooms) contain
various types of biologically active, high-molecular (e.g., ß-
glucans) and low-molecular compounds (e.g., triterpenes,
lectins, steroids) in fruiting bodies, spores, culture mycelia and
culture broth, with suggested anticarcinogenic effects (Wasser
andWeis, 1999; Wasser, 2017). They contain various compounds
that intervene in signaling pathways of tumor-specific
proliferation, regulation of apoptosis, cancer-specific
metabolism, angiogenesis, metastasis and key functions of the
immune system (Blagodatski et al., 2018).
Several extracts from medicinal mushrooms such as
polysaccharides and in particular ß-glucans, e.g., krestin and
polysaccharide peptide (PSP) from Coriolus versicolor, and
lentinan, isolated from Lentinula edodes (Shiitake), have been
investigated in vivo, in vitro and in studies in humans (Joseph
et al., 2018). Many clinical studies have been conducted on the
complementary use of these substances, e.g., in conjunction with
chemotherapy. The results indicate relevant health benefits such
as overall disease-free survival of colorectal cancer patients and in
improving quality of life among lung cancer patients (Sakamoto
et al., 2006; Zhang et al., 2018). A wide range of antitumoral or
immunostimulating polysaccharides with different chemical
structure from higher basidiomycetes mushrooms has been
widely investigated (Wasser, 2002). Medicinal mushrooms
have been approved for more than 30 years in Japan and
China as an adjunct to standard cancer treatments and have
an extensive clinical history of safe use as a single agent or in
combination with chemotherapy (Rossi et al., 2018).
Although very popular in East Asia, medicinal mushroom
therapies are still largely unknown in Western countries,
especially in conventional medical institutions. The medicinal
use of mushrooms is becoming wide known within the CIM
communities of Europe and the United States. The number of
studies on medical mushrooms in oncology has increased in
recent decades (Joseph et al., 2018). Apart from focusing on
certain mushroom-derived mono-substances, such as PSP,
lentinan and krestin, research into the entire spectrum of
mushroom formulations is considered promising. The large
number of active ingredients of medicinal mushrooms is
suspected to synergistically act on several cancer-related
pathways (Wasser, 2017; Joseph et al., 2018).
A single mushroom species may contain several of active
ingredients which have the potential to influence several
cancer-related processes in a synergistic way (Blagodatski
et al., 2018; Joseph et al., 2018). As such research on
complex synergistic anticancer effects caused by
combinations of molecules in mushroom extracts seems
particularly important.
The purpose of this narrative review was to evaluate clinical
trials (CTs) investigating the effects of medicinal mushrooms in
the supportive, complementary therapy of cancer patients during
and/or post conventional care. They are currently mostly multi-
substance formulations and are available in the form of powders,
tablets, capsules or other extract forms. In this paper we focused
on clinical studies which investigated the effects of these
formulations on immune function, quality of life, well-being
and their adverse effects.
METHODS
We searched MEDLINE, EMBASE CENTRAL, the Web of
Science, ClinicalTrials.gov and the WHO International CTs
Registry Platform Search Portal from inception until June
2020, with no restrictions on the date of publication. Studies
were included, if they 1) investigated cancer patients, 2) included
whole spectrum mushroom formulations, 3) were in English
language, and 4) were used as complementary therapy during
or after conventional cancer treatment. Studies were excluded, if
they 1) had study designs other than controlled CT or
randomized controlled trials (RCT), 2) were animal studies or
in vitro studies, or 3) investigated participants with no cancer
diagnosis. The study protocol was reviewed and approved by the
ethics committee of the Charité-University Medical Center,
Berlin, Germany, registration number EA1/172/19. The study
was not registered at a CTs registry.
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TABLE 1 | Overview of studies included in this review.















divided into 2 daily
doses (6 tablets per
day, 3 in the morning
and 3 in the
afternoon, between
meals) for a period of
6 months
Agaricus sylvaticus RCT, placebo-
controlled,
double-blind
46 6 months Chemotherapy-
associated adverse
effects
Patients in the verum group had
reduced chemotherapy-associated
adverse effects (nausea, vomiting
and anorexia)
(Fortes et al., 2008;
Fortes et al., 2009;








day), divided into 2
daily doses (6 tablets
per day, 3 in the
morning and 3 in the
afternoon, between
meals)
Agaricus sylvaticus RCT, placebo-
controlled,
double-blind
56 6 months Blood count, iron,
fasting glucose, BMI,
blood pressure
Beneficial effects in the verum group
regarding hematological parameters
and a reduction of fasting plasma
glucose levels and blood pressure.
No effects on BMI.













40 Intake 7 weeks Primary end points: 1)









both measured on the
day of inclusion and at
the end of intake of the
study product, and 3)
differences in the stem
cell harvest product of a
number of mononuclear
cell subsets associated
with the immune system.
Secondary end points:
1) clinical response to
treatment, 2) time in
neutropenia, 3) days
with body temperature
above 38°C, 4) days with
IV antibiotics after stem
cell infusion, 5) time to
new treatment, 6) OS,
and 7) quality of life
In the leukapheresis product
harvested after stem cell
mobilization, increased percentages
of treg cells (CD4+/CD127d+/CD25)
and plasmacytoid dendritic cells
(CD303+) were found in patients
receiving verum. A significant
increase in serum levels of IL-1, IL-5
and IL- 7 was observed at the end of
treatment in the verum
group.Increased expression of
immunoglobulin genes, killer
immunoglobulin receptor genes and
HLA genes were observed in the
verum group there were no
statistically significant differences in
treatment response, OS, time in
neutropenia, temperature above 38
°C and time to new treatment in the
verum group, trends were observed
for a longer median time to next
treatment and a shorter duration of IV
antibiotic treatment. Health related
quality of life assessment revealed no
differences between the study
groups
































TABLE 1 | (Continued) Overview of studies included in this review.




















100 Every 3 weeks for at
least 3 cycles of
chemotherapy
Immunological status,
side effects, quality of life
Natural killer cell activity was
significantly higher in the verum
group. No significant difference in
lymphokine-activated killer and
monocyte activities was observed in
a manner similar to the count of
specific immune cell populations
between the groups.
Chemotherapy-associated side
effects such as appetite, alopecia,
emotional stability, and general
weakness were improved by verum
only







Extract, 20 ml, 2×/
day
Antrodia cinnamomea RCT, placebo-
controlled,
double-blind
37 30 days The primary endpoint
was 6-months OS; the
secondary endpoints
were DCR, QoL and
biochemical parameters
Mean OSs were 5.4 months for the
verum group and 5.0 months for the
placebo group (p  0.340), and the
DCRs were 41.2 and 55%,
respectively (p  0.33). Most
hematologic, liver, or kidney
functions did not differ significantly
between the two groups, but platelet
counts were lower in the verum
group than in the placebo group (p 
0.02). QoL assessments were similar
in the two groups, except that the
verum group showed significant
improvements in quality of sleep (p 
0.04)
(Chay et al., 2017) Advanced hepatocellular
carcinoma
Extract, 2.4 g/day Coriolus versicolor RCT - 2:1 to
either verum or
placebo
15 Median treatment time
2.5–4.2 months
The primary endpoint





qol, PFS and OS.
There was no difference in TTP with
use of verum compared to placebo.
Verum had better social and
emotional functioning scores and
less appetite loss and pain
symptoms compared to placebo
subjects during treatment




Spore powder, 1 g
3×/day for 4 weeks
Ganoderma lucidum RCT, placebo-
controlled
48 4 weeks FACT-F, HADS, EORTC
QLQ-C30, TNF-α, IL-6
The verum group showed statistically
significant improvements in the
domains of physical well-being,
fatigue and overall quality of life and
less anxiety/depression after
intervention compared to placebo.
TNF-α and IL-6 were lower in the
verum group compared to placebo
































TABLE 1 | (Continued) Overview of studies included in this review.









(Oka et al., 2010) Colorectal adenoma Extract, 1.5 g/day Ganoderma lucidum CCT 198 12 months Size, site and
macroscopic type of all
adenomas
The changes in the number of
adenomas up to 12 months
increased to 0.66 ± 0.10 in the
control group, while decreasing in
the verum group to −0.42 ± 0.10 (p <
0.01). The total size of adenomas
increased to 1.73 ± 0.28 mm in the
control group and decreased to
−1.40 ± 0.64 mm in the verum group
(p < 0.01)
(Gao et al., 2003a) Advanced lung cancer Extract, 600 mg 3×/
day
Ganoderma lucidum RCT, placebo-
controlled,
double-blind
68 12 weeks Karnofsky performance
status, immunological
parameters
Treatment with verum showed a
stable disease in 35% lung cancer
patients at the 12-weeks visit, which
was significantly higher than in the
control group (22%). Treatment with
verum resulted in a significant
increase in karnofsky scores (>10
scores) in 50% of the patients
compared to placebo (14% in
placebo group) cancer-related
symptoms (e.g., fever, cough,
weakness, sweating and insomnia)
were significantly improved in
43–84% of cancer patients receiving
verum compared to placebo
(11–43%). Verum showed a
significant increase in lymphocyte
mitogenic reactivity to concanavalin
A, CD3 percentage and natural killer
cell activity compared to placebo
RCT, Randomized Controlled Trial; CCT, Controlled Clinical Trial; BMI, Body Mass Index; OS, overall survival; DCR, disease control rate; QoL, quality of life; TTP, time to progression; PFS, progression-free survival; EORTC-QLQC30,
European organization for research and treatment - quality of life questionnaire; HADS, Hospital Anxiety and Depression Scale; FACT-Hep, Functional Assessment of Cancer Therapy - Hepatobiliary Cancer; IV, intravenous; CD, cluster of

































Our search yielded a total of 272 studies from the electronic
databases. After sorting out repetitive hits, irrelevant and several
single arm studies with various outcomes, e.g., dose escalation
studies (Kodama et al., 2002; Gao et al., 2003b; Yoshimura et al.,
2010; Palomares et al., 2011; Torkelson et al., 2012; Ohno et al.,
2013; Suzuki et al., 2013; Twardowski et al., 2015) as well as many
publications on in vitro and animal models, nine studies met our
inclusion and exclusion criteria for a narrative review on
medicinal mushrooms in human cancer therapy (eight RCTs,
one CCT) (Table 1). A large variety of cancer entities, studied
sample sizes, outcomes, treatment durations and observation
times were seen (Table 1). The medicinal mushrooms
investigated were Agaricus sylvaticus (two trials) (Fortes et al.,
2008; Costa Fortes et al., 2010; Costa Fortes and Carvalho Garbi
Novaes, 2011; Valadares et al., 2013), Agaricus blazei murill (two
trials) (Ahn et al., 2004; Tangen et al., 2015), Antrodia
cinnamomea (one trial) (Tsai et al., 2016), Coriolus versicolor
(one trial) (Chay et al., 2017) and Ganoderma lucidum (three
trials) (Gao et al., 2003a; Oka et al., 2010; Zhao et al., 2012). All
mushrooms were administered orally. Four articles were by
Fortes et al. and they described different results of a study
with Agaricus sylvaticus which included 56 colorectal cancer
patients (Fortes et al., 2008; Fortes et al., 2009; Costa Fortes
et al., 2010; Costa Fortes and Carvalho Garbi Novaes, 2011).
These four articles were presented as one study. Most studies were
named as placebo-controlled, double-blind RCTs. The
methodological quality of most studies was generally
unsatisfactory and most results were poorly reported in many
aspects.
According to the included studies medicinal mushrooms
appear to facilitate improvements in: 1) quality of life, 2) a
reduction of side effects by conventional therapy (e.g.,
chemotherapy), 3) hematologic parameters, 4) overall survival
(OS), antitumor activity and immunomodulation. Furthermore
5) medicinal mushrooms seem to be safe. These points are
presented in detail below:
Quality of Life
Chay et al. investigated effects of Coriolus versicolor as a
complementary therapy in a RCT with 15 patients with
advanced hepatocellular carcinoma (HCC) who had poor liver
function or were ineligible for standard therapy (Chay et al.,
2017). Participants in the verum group reported improved
emotional, physical, social and cognitive function compared to
the placebo group on the European organization for research and
treatment - quality of life questionnaire (EORTC-QLQC30)
during the treatment. However, this was not statistically
significant between the groups. Based on the Functional
Assessment of Cancer Therapy - Hepatobiliary Cancer
(FACT-Hep) questionnaire, the lowest values for physical and
emotional well-being reported by the subjects in the verum group
were on average higher than those reported by patients receiving
placebo during the treatment.
Fortes et al. investigated 56 patients with colorectal cancer
after surgery over a period of 6 months, randomly assigned to the
intake Agaricus sylvaticus or placebo (Costa Fortes et al., 2010).
Analyses did not show significant differences regarding quality of
life, however the results after 6 months showed a tendency toward
better mood and sleep, and less gastrointestinal symptoms and
pain in the verum group.
Tsai et al. observed quality of life in a RCT (Tsai et al., 2016).
Thirty seven patients with advanced adenocarcinomas of breast,
lungs, stomach, liver and colorectal region undergoing
chemotherapy were enrolled and randomized to a 30-days-
supplementary treatment with Antrodia cinnamomea or
placebo. Assessments of the EORTC-QLQ-C30 showed no
significant differences between the groups other than sleep,
which was significantly improved in the verum group (p  0.04).
Ahn et al. conducted a RCT including 100 patients with different
gynecological cancers (cervical, endometrium and ovarian) receiving
chemotherapy and Agaricus blazeii murill Kyowa or placebo (Ahn
et al., 2004). Patients showed improvements in terms of mood
parameters (anxiety, depression, mental stability) and body strength
compared to placebo on a modified EORTC-QLQ-C30. Between-
group differences were not reported.
In a RCT of Zhao et al. investigating 48 breast cancer patients
with cancer-related fatigue undergoing endocrine therapy the
subscales on the EORTC QLQ-C30 physical function (verum:
week 0: 63.7 ± 25.9, week 4: 78.2 ± 26.1; placebo: week 0: 64.0 ±
27.1, week 4: 64.5 ± 28.7) and global quality of life (verum: week 0:
55.8 ± 22.9, week 4: 68.9 ± 21.4; placebo: week 0: 56.6 ± 23.0, week
4: 57.7 ± 24.2) were significantly (p < 0.01) improved after a 4-
weeks treatment with spore powder of Ganoderma lucidum
compared to placebo (Zhao et al., 2012). Also, the parameters
fatigue (verum: week 0: 39.76 ± 5.10, week 4: 46.78 ± 5.07;
placebo: week 0: 40.35 ± 6.10, week 4: 40.92 ± 5.62), sleep
disturbance (verum: week 0: 56.5 ± 21.8, week 4: 42.3 ± 26.2;
placebo: week 0: 55.8 ± 22.6, week 4: 53.9 ± 24.8) and loss of
appetite (verum: week 0: 32.5 ± 19.3, week 4: 24.3 ± 18.4; placebo:
week 0: 32.3 ± 17.4, week 4: 30.3 ± 16.5) among patients in the
verum group improved significantly (p < 0.01, p < 0.01 and p <
0.05, respectively) on the EORTC QLQ-C30 and FACT-F. In
addition, anxiety (verum: week 0: 6.3 ± 3.2, week 4: 4.1 ± 2.9;
placebo: week 0: 6.5 ± 3.4, week 4: 6.1 ± 3.2) and depression
(verum: week 0: 4.9 ± 3.8, week 4: 3.1 ± 2.8; placebo: week 0: 4.8 ±
3.1, week 4: 4.6 ± 2.9) on the Hospital Anxiety and Depression
Scale improved significantly (p < 0.05 and p < 0.01, respectively)
compared to the control group.
Health related quality of life assessment revealed no
differences between the study groups on the EORTC QLQ-C
30 questionnaire in a RCT with patients with multiple myeloma
undergoing high dose chemotherapy and autologous stem cell
transplantation (verum: Agaricus blazei Murill) (Tangen et al.,
2015).
In a RCT of Gao with patients with advanced lung cancer
treatment with Ganoderma lucidum resulted in a significant
increase in Karnofsky scores (i.e., in >10 scores) in 50% of the
32 verum patients compared to placebo (in comparison to 14% of
the 29 patients in the placebo group) (Gao et al., 2003a). Nine
(28%) and seven (22%) patients receiving verum had unchanged
and reduced Karnofsky scores in comparison to 13 (46%) and 11
(39%) in the placebo group.
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Reduction of Side Effects by Conventional
Therapy
Valadares et al. focused on the effects of Agaricus sylvaticus
extract (2.1 g/day for a period of 6 months) on side effects of
chemotherapy in breast cancer patients in a RCT (Valadares et al.,
2013). Patients with three cycles of chemotherapy at the
beginning of treatment reported poor appetite, with 23% of
these patients in the placebo group and 54% of these patients
in theAgaricus sylvaticus group. After 3 months of treatment with
Agaricus sylvaticus, 31% of patients in the placebo group reported
a reduction in appetite, while no such symptoms occurred in the
supplemented group. Compared to patients with six cycles of
chemotherapy and use of Agaricus sylvaticus, the data showed
that, toward the end of the treatment, loss of appetite decreased
over time. In comparison, 80% of patients in the placebo group
complained about loss of appetite by the end of the study after 6
months. While the majority of the placebo-receiving patients
suffered from gastrointestinal symptoms like diarrhea,
constipation, nausea and vomiting, only two patients in the
verum group reported these side effects. Patients taking
medicinal mushrooms had nearly no loss of appetite and only
in a few cases fever was an occurrence while this was also frequent
in the placebo group.
In the RCT of Chay et al. lower average symptom scores for
nausea, vomiting, pain, insomnia, constipation, and diarrhea
were reported by patients supplemented with Coriolus
versicolor during conventional treatment of HCC patients
compared to placebo (Chay et al., 2017). Verum patients also
experienced significantly less pain (group difference: −38.6 95%
CI: 65.5 to −11.8; p  0.011) and loss of appetite (group difference:
39.7 95% CI: 64.5 to −15.0, p  0.006) during treatment compared
to placebo patients.
Ahn et al. showed in a RCT that patients with gynecological
cancers receiving chemotherapy suffered from fewer side effects
such as loss of appetite, alopecia, emotional instability and general
weakness when the therapy was complemented with Agaricus
blazeii murill compared to placebo (Ahn et al., 2004). Participants
completed a questionnaire that sought data on physical and
emotional status of the patients. These include insomnia,
appetite, alopecia, body weight, nausea/vomiting, emotional
conditions, discomfort, and general body strength. In this
study a figure only reported these results. Detailed results were
not available.
In the RCT of Tsai et al. patients with advanced
adenocarcinomas were treated with Antrodia cinnamomea
alongside chemotherapy. While gastrointestinal symptoms
such as abdominal pain and diarrhea were observed more
frequently in the verum than in the placebo group (8 vs. 6).,
their intensity was lower (grade 1 and 2) compared to the placebo
group (grade 3 and 4) (Tsai et al., 2016). Four patients suffered
severe abdominal pain receiving placebo due to disease
progression.
In advanced lung cancer, several cancer-related symptoms
such as fever, cough, weakness, sweating and insomnia improved
significantly in 43–84% of patients receiving Ganoderma lucidum
compared to placebo (11–43%) (Gao et al., 2003a).
Hematological Parameters
Fortes et al. observed in a RCT beneficial hematological and
glycaemic effects of dietary supplementation with Agaricus
sylvaticus in patients with colorectal cancer after surgery
(Fortes et al., 2008; Costa Fortes et al., 2010; Costa Fortes and
Carvalho Garbi Novaes, 2011). The verum group showed
significant within-group reductions of fasting plasma glucose,
cholesterol, creatinine, aspartate aminotransferase, alanine
aminotransferase, immunoglobulin A, immunoglobulin M,
systolic and diastolic blood pressure and an improvement in
hematological parameters (e.g., hemoglobin, hematocrit,
erythrocytes, iron) after 3 and 6 months of treatment, whereas
in the placebo group no significant within-group changes were
observed. No effects on weight and body mass index were
observed. Between-group differences were not calculated.
In the RCT of Tsai et al. most hematological, liver or kidney
functions did not differ significantly between the two groups, but
platelet counts were lower in the Antrodia cinnamomea group
than in the placebo group (p  0.02) (Tsai et al., 2016).
Survival, Antitumor Activity and
Immunomodulation
In the latter RCT the supplemental therapy with Antrodia
cinnamomea for chemotherapy in advanced adenocarcinomas
showed no significant difference in OS compared to placebo (Tsai
et al., 2016). Progression of the disease was the leading cause of
death in four (33.3%) verum and eight (66.7%) placebo recipients.
Mean OS was 5.4 months in the verum group and 5months in the
placebo group (p  0.340), and disease control rates were 41.2%
and 55% respectively (p  0.33).
In the RCT with patients with advanced HCC treated with
Coriolus versicolor, trends toward longer median OS compared to
placebo (6.5 vs. 2.2 months, Coriolus versicolor vs. placebo) and
median progression-free survival (2.5 vs. 1.1 months) were
observed (Chay et al., 2017). The time to progression (TTP)
was not significant (2.5 vs. 4.2 months).
Oka et al. showed in a CT that a water-soluble extract from the
culture medium of Ganoderma lucidum mycelia suppressed the
development of colorectal adenoma (Oka et al., 2010). Follow-up
colonoscopy was performed after 12 months, 96 patients
completed the trial. One hundred two patients in the no-
treatment control group were selected randomly. The changes
in the number of adenomas up to 12 months increased to 0.66 ±
0.10 in the control group, while decreasing in the verum group to
−0.42 ± 0.10 (p < 0.01). The total size of adenomas increased to
1.73 ± 0.28 mm in the control group and decreased to −1.40 ±
0.64 mm in the verum group (p < 0.01).
Chay et al. observed no difference in the use of Coriolus
versicolor compared to placebo regarding the primary
endpoint TTP in advanced HCC treated with chemotherapy.
The median duration of the treatment in the placebo and verum
armwas 1.5 cycles and three cycles, respectively. Median TTP was
2.5 (1.4–5.3) months compared to 4.2 (0.4–4.2) months in the
verum and placebo arm, respectively, with a hazard ratio (HR) of
0.70 (0.16–3.05 p  0.634). Median progression-free survival was
2.5 (1.4–5.3) months in the verum and 1.1 (0.4–4.2) months in the
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placebo arm, HR 0.42 (0.13–1.34, p  0.144). Median OS was 6.5
(3.3–24.1) and 2.2 (0.8–23.3) months, respectively, HR 0.35
(0.10–1.25, p  0.105). In addition, the group examined the
serum concentration of potentially relevant markers for HCC.
They found a decrease in interleukin (IL)17F, MCP-1 and
increase in prolactin and TNF-related apoptosis-inducing
ligands in patients with HCC treated with Coriolus versicolor
compared to placebo (Chay et al., 2017).
The activity of natural killer cells in patients with
gynecological cancers undergoing chemotherapy was
significantly increased in the verum group treated with
Agaricus blazei murill after 3 and 6 weeks compared to
placebo (Ahn et al., 2004). No difference was observed in the
number of white blood cells, monocytes, lymphocytes, T cells,
cluster of differentiation (CD) 48+ and CD 56+ cells.
In an RCT Tangen et al. investigated the effects of Agaricus
blazei Murill supplementation on multiple myeloma patients
undergoing high dose chemotherapy and autologous stem cell
transplantation. They found no statistically significant differences
in treatment response, OS and time of treatment between patients
supplemented with AndoSan (containing 82.4% of Agaricus
blazei Murill) and placebo (Tangen et al., 2015). In the verum
group, trends toward a longer median time to the next treatment
(37.5 vs. 31.2 months) and a shorter duration of intravenously
(IV) antibiotic treatment (8.6 vs. 10.0 days) were observed.
Moreover beneficial effects on immunological parameters were
found in the verum group only: 1) a significant increase in serum
levels of IL 1ra, IL-5 and IL-7, 2) an increased expression of
immunoglobulin genes, KIR genes and HLA-genes and 3) in the
leukapheresis product harvested after stem cell mobilization,
increased percentages of Treg cells (CD4+/CD127d+/Cd25+)
and plasmacytoid dendritic cells (CD303+).
Ganoderma lucidum supplementation resulted in a stable
disease condition in 35.1% of the study population suffering
from lung cancer at the 12 week’s visit (Gao et al., 2003a). This
was significantly higher than in the control group (22.6%).
Moreover, a significant increase in lymphocyte mitogenic
reactivity to concanavalin A (baseline: 52.3 ± 11.5, after
treatment: 68.9 ± 8.9, p < 0.05), CD3 percentage (baseline: 46.2 ±
11.3, after treatment: 55.8 ± 10.5, p < 0.05) and natural killer cell
activity (baseline: 24.1 ± 12.3, after treatment: 42.8 ± 19.7, p < 0.05)
was shown; a marginal increase in CD4 percentage and CD4/CD8
ratio; but a marginal decrease in CD8. All of these immune
parameters remained unchanged or decreased in the control group.
Safety of Medicinal Mushrooms
Adverse events of treatment with medicinal mushrooms were
poorly reported. Only in three trials there was an explicit
reference to such events (Oka et al., 2010; Zhao et al., 2012;
Tsai et al., 2016). No serious adverse events due to medical
mushroom intake were reported.
Adverse effects attributed to the mushrooms were a significant
decrease in platelet cell count within normal ranges during a 30-
days treatment with Antrodia cinnamomea and a 6-months
treatment with Agaricus sylvaticus (Fortes et al., 2009; Tsai
et al., 2016), while all other laboratory values in the verum
groups were stable or improved.
In the CCT among patients with colorectal adenoma treated
with Ganoderma lucidum adverse events were noted in six out
of 123 patients in the verum group (Oka et al., 2010). Symptoms
were diarrhea (n  4), stomach discomfort (n  1) and poor
health (n  1). Treatment with the verum was discontinued in
all cases. No adverse events were reported for the placebo group
(n  102).
The incidence of gastrointestinal reactions, including
abdominal pain and diarrhea, was much greater in the
Antrodia cinnamomea group (47%) than in the placebo group.
The adverse events observed in patients treated with Antrodia
cinnamomea were generally consistent with its known adverse
event profile (Tsai et al., 2016).
In the RCT of Zhao et al. examining breast cancer patients
with cancer-related fatigue undergoing endocrine therapy treated
withGanoderma lucidum no serious adverse effects were reported
during the study. Only “mild discomfort”was recorded, and these
are shown in a table for the verum group only. The two most
common discomfort were dizziness (16%) and dry mouth (12%)
(Zhao et al., 2012).
The study using Ganoderma lucidum in advanced lung cancer
describes three episodes of mild toxicity (nausea: 2; insomnia: 1)
in the verum and one episode of toxicity (vomiting) in the control
group (Gao et al., 2003a).
DISCUSSION
The studies evaluated in this narrative review suggest that the
use of medicinal mushrooms may improve cancer-related and
treatment-related symptoms in patients with different types and
stages of cancer when used as a complementary therapy
alongside conventional cancer care. Most studies considered
in this paper showed beneficial effects in favor of medicinal
mushrooms for various cancer entities, especially with regards
to quality of life and reduction of side effects of conventional
oncological treatment (particularly chemotherapy and
endocrine therapy). Also, positive effects on antitumor
activity and immunomodulation were reported, e.g., an
increased activity of natural killer cells. In addition, there was
some uncertain evidence of a longer survival of cancer patients
treated with medicinal mushrooms, although in most studies
the effect was not significant when compared to placebo.
Adverse or negative effects of the used extracts were rarely
reported. The only reported adverse effects being
gastrointestinal reactions and decrease in platelet count. No
serious adverse event due to medical mushroom intake was
reported in the reviewed studies.
Reduced quality of life and fatigue are common side effects of
conventional cancer treatment and the disease itself (Visser and
Smets, 1998; Bottomley, 2002). Most studies observed
improvements in various aspects of quality of life. Moreover,
emotional and mental well-being, and mood scores (particularly
anxiety and depression) also improved in some studies (Ahn
et al., 2004). A Cochrane review of Ganoderma lucidum for
cancer treatment showed that patients in the Ganoderma
lucidum group had a relatively better quality of life compared
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to controls (Jin et al., 2016). Moreover, sleep disorders affect
30–50% of cancer patients and contribute to additional risks of
depression, fatigue, increased pain and reduced survival rates
(Otte et al., 2015). Some studies in this review showed an
increased quality of sleep associated with medicinal mushroom
intake (Fortes et al., 2008; Tsai et al., 2016; Chay et al., 2017). In
addition, several mushroom species are suspected to have an anti-
fatigue effect (Geng et al., 2017).
Also, reduction of chemotherapy-related adverse effects was
reported. Several common side effects (nausea, vomiting, pain
and hair loss) were reduced in most of the studies reviewed in
this paper.
Leukopenia, especially lymphopenia and neutropenia, are
consequences of cachexia and the metabolic changes caused by
the tumor and increase the risk of infection (Wasser and Weis,
1999). In patients with multiple myeloma, the immune status was
much better in terms of white blood cells and immunoglobins,
which also led to fewer infections when treated with Agaricus
blazei murill (Tangen et al., 2015). Medicinal mushrooms could
help to counteract bone marrow suppression induced by chemo-
and radiotherapy (Hofer and Pospisil, 2011). Their main
component, ß-glucans, have hematopoietic effects and improve
bone marrow regeneration in vitro (Sorimachi et al., 2001).
Several reviewed studies showed a possible improved
therapeutic response to chemo- and radiotherapy. Tsai et al.
observed an advantage in the 6-months OS and mortality rate in
favor of Antrodia cinnamomea (Tsai et al., 2016). The medicinal
mushroom preparation was given for 4 weeks, most likely too
short a duration to produce significant changes. In vitro studies
with Antrodia cinnamomea showed inhibition of the growth of
breast cancer cells, including MCF-7 cells and tamoxifen-
resistant MCF-7 cell lines, and sensitization of radio/
chemotherapy of cancer stem cells (CSC) by modulation of
microRNA expression (Su et al., 2017; Lin et al., 2018).
Another in vitro study showed an association between the
CSC-inhibitory effect of Antrodia cinnamomea and significant
downregulation of several microRNAs and cancer stemness
expression levels in brain and breast CSCs (Su et al., 2017).
A Cochrane review of five RCTs using Ganoderma lucidum
showed that cancer patients (especially lung cancer, colon cancer,
breast cancer) in the verum group were more likely to respond
positively compared to placebo and chemo/radiotherapy alone
(RR 1.50; 95% CI 0.90 to 2.51, p  0.02) (Jin et al., 2016). The
treatment with Ganoderma lucidum alone did not show the same
regression rate as the combined therapy.
A meta-analysis including 1,094 patients with curatively
resected colorectal cancer treated with polysaccharide K, a
main ingredient of Coriolus versicolor, showed an OS risk ratio
of 0.71 (95% CI: 0.55–0.90; p  0.006). The disease-free survival
risk ratio was 0.72 (95% CI: 0.58–0.90; p  0.003) (Sakamoto et al.,
2006).
Another meta-analysis including 3,117 patients of 38 RCTs in
China showed an overall response rate in treating lung cancer
treated with lentinanIV (1–1.5 mg/d, 2–8 weeks, depending on
the study), a main ingredient of Lentinula edodes, was increased
from 43.3% of chemotherapy alone to 56.9% of lentinan plus
chemotherapy. Compared with chemotherapy alone, lentinan
plus chemotherapy showed more efficacy in treating lung
cancer (pooled RR 0.79, 95% CI: 0.74–0.85) (Zhang et al., 2018).
Altogether, adverse effects were rarely reported.
Gastrointestinal symptoms were the most common
problem, which may be due to the high amount of dietary
fiber and prebiotics known to cause mild stomach upset such
as bloating, abdominal pain, diarrhea and constipation. Tsai
et al. observed a significant decrease in platelet count in
patients treated with Antrodia cinnamomea, despite the
short treatment duration of 30 days (Tsai et al., 2016). The
data indicated a large difference in the decline in platelet levels
between the two groups in patients with lung cancer (84 vs.
5%) and gastric cancer (22 vs. 5%) which could not be
explained properly. Also patients with colorectal cancer
treated for 6 months with Agaricus sylvaticus showed
reduced platelet counts compared to placebo (Fortes et al.,
2009). The relevance of a reduced platelet count was unclear
and needs further investigation. The assessment of adverse
effects of medicinal mushrooms as well as the correct dosage
and possible drug interactions must be further clarified in
future CTs.
The postulated mechanisms of action are still vague and
diverse. Secondary metabolites of medicinal mushrooms may
produce health benefits and anticancer effects by activating stress
resistance mechanisms, including autophagy, DNA repair and
expression of antioxidant enzymes (Kalaras et al., 2017; Martel
et al., 2020). Medicinal mushrooms are recognized as
immunomodulators and anti-cancer agents that are able to
disrupt certain cellular signal transmission pathways, which
are associated with cancer development and progression (De
Silva et al., 2012). The biochemical mechanisms that mediate this
biological activity are still not clearly understood. Several
pathways, antiproliferative and immunomodulatory effects
triggered by medicinal mushrooms have been described (Aras
et al., 2018; Ayeka, 2018; Joseph et al., 2018; Rossi et al., 2018).
Mushroom polysaccharides are known to stimulate latent natural
killer cells, T cells, B cells and macrophage-dependent immune
system responses (Wasser, 2017). Several species of medicinal
mushrooms have shown anti-tumour properties in experimental
studies (Wasser, 2011). However, much of the evidence is based
on results of in vitro assays as well as in vivo animal data (De Silva
et al., 2012).
Compounds of mushrooms may produce hermetic dose-
response effects, with potentially beneficial effects at low doses
and toxic effects at high doses in normal cells, while in cancer cells
only the toxic effects at high doses are potentially beneficial
(Calabrese, 2005). The supposed hormetic effects of
fungochemicals seem to be relatively modest in humans,
which may explain why such effects are observable in animal
models but less obvious in clinical studies (where several variables
and opposing factors may dilute such effects).
Natural killer cells play an important role in innate immunity
by recognizing major histocompatibility class I-negative target
cells, which can escape immune surveillance by cytotoxic T cells.
A Cochrane review of five RCTs using Ganoderma lucidum as
complementary cancer therapy showed that patients in the verum
group had increased natural killer cell activity and increased levels
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of CD3, CD4 and CD8, leukocytes, and CD4/CD8 ratio (Jin et al.,
2016).
Moreover there is evidence that orally taken medicinal
mushrooms have an influence on the microbiome (Friedman,
2016; Jayachandran et al., 2017; Grant et al., 2019). Medicinal
mushrooms could act as prebiotics that can stimulate the growth
of beneficial microbiota. Prebiotics can modulate the human
intestinal microbiota and can attenuate various disease such as
diabetes, obesity and cancer (Rossi et al., 2018). The important
sources of prebiotics in mushrooms are indigestible
polysaccharides, which can inhibit the proliferation of
pathogens by promoting the growth of probiotic bacteria in
the gut (Singdevsachan et al., 2016). Poor intestinal microbiota
can contribute to the development of cancer and various
metabolic disorders leading to inflammation in the intestine,
liver and brain (Boulangé et al., 2016; Vivarelli et al., 2019).
Isolated substances from medicinal mushrooms such as crestin
and lentinan administered IV are most likely to have different
mechanisms of action in vivo than orally taken full-spectrum
mushroom formulations. Future studies are necessary to
compare the effects of extracts and isolated substances.There
is a lack of conclusive evidence on dosage of medicinal
mushrooms. First in vivo dose escalation studies were
identified. Torkelson et al. conducted a controlled dose
escalation study with nine breast cancer patients undergoing
radiation therapy receiving Coriolus versicolor for 6 weeks
(Torkelson et al., 2012). A faster recovery was observed in
the medium and high dose patients (6 and 9 g/day). Further
research is needed to determine the correct dose of medicinal
mushrooms, as well as possible interactions with
chemotherapeutic agents, in order to make it a safe
treatment during conventional cancer therapy. In addition,
the quality of the products is of crucial importance, as
contamination with mold, pesticides and heavy metals could
be a problem for herbal products from natural sources (Harris
et al., 2011).
There are several relevant limitations to the reviewed studies,
particularly the small study populations (ranging from n  15 to
n  198), short treatment periods (ranging from 3 weeks to
6 months), studies examining various tumor entities (breast,
ovarian, endometrial, colorectal, lung, hepatocellular cancer,
multiple myeloma), lack of information about the exact
ethnicity of the study participants and non-standardized
mushroom preparations. The methodological quality of most
studies was unsatisfactory and most results were poorly
reported in many respects (especially between-group
comparisons were missing quite often). Future studies should
be reported with the assistance of the Consolidated Standards of
Reporting Trials statement. In addition, detailed information
about production, composition and bio-active ingredients were
mentioned only in a few of the reviewed studies and there only
partially. Furthermore, this review included only English
publications. It is likely that further studies can be found in
Chinese and Japanese databases. Four out of five RCTs of the
Cochrane review were in Chinese and were published in Chinese
journals (Jin et al., 2016).
CONCLUSION
This narrative review shows possible potential of medicinal
mushrooms in complementary cancer treatment. Promising
anticarcinogenic effects have been documented in vitro and
in vivo for several medicinal mushrooms. However, only few
clinical studies defined OS or time to disease progression as
primary endpoints. Others were too short in duration as to be
fitting to strengthen this hypothesis. Immunomodulating effects
such as the proliferation of lymphatic cell lines,
immunoglobulins and cytokines have also been documented
in humans.
It is likely that medicinal mushrooms could improve quality of
life during and after conventional cancer therapy. Their prebiotic
effects pose a possible explanation, as do other, yet unknown
effects. A better emotional and physical status, better sleep and
less fatigue, as well as fewer side effects of conventional
chemotherapy such as nausea, vomiting and gastrointestinal
symptoms could be observed in the reviewed CTs on patients
taking medicinal mushrooms.
Adverse events of treatment with medicinal mushrooms were
poorly reported but appeared to be rare. The relevance of a
reduced platelet count remains unclear and requires further
investigation. The correct dosage and possible drug
interactions also need to be further clarified in future clinical
studies. There is an urgent need to investigate efficacy and safety
of medicinal mushrooms in well planned CTs as more and more
patients use mushrooms as a co-medication.
However, current knowledge does not support the routine
use of medicinal mushrooms in cancer patients. The decision
whether to use medicinal mushrooms as an add-on treatment
in cancer care should remain patients’ preferences for now,
assisted by evidence-informed physicians. Currently, evidence
for the use of medicinal mushrooms in cancer is rather scarce
and the methodological quality of most of the reviewed studies
is poor. The existing evidence only allows for preliminary
conclusions. The lack of standardization in several aspects of
the included studies, such as inconsistent preparation methods
and different modes of administration of medicinal
mushrooms as well as the lack of key information in the
reviewed publications, reduces the reliability and validity of
those studies.
A special feature of medicinal mushrooms might be, as they
produce hundreds of active compounds, that they may influence
several cancer-related processes in a synergistic way. Therefore, not
only studies on certain mushroom-derived compounds are
warranted, but also further research on complex anticancer effects
facilitated by combinations of molecules could be of great interest.
In summary, despite the promising preliminary data, more
scientific work needs to be done to clarify the use of medicinal
mushrooms in cancer therapy. Particularly, further clinical
research is needed, including methodologically high-quality
studies, larger sample sizes, standard mushroom preparations
and longer-term follow-up studies. In addition, future studies
should also investigate the preventive aspects of medicinal
mushrooms, as medicinal mushrooms or more common types
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of mushrooms can also be effective in reducing cancer incidence
as part of a healthy diet and lifestyle (Li et al., 2014).
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